Fairvalue-Calculator Fairvalue-Calculator
EN DE

LTR Pharma Limited (LTP) Fair Value & Analysis

Healthcare · AU · Market cap A$84.5M

PriceA$0.5650
Fair ValueA$0.7800
Upside+38.1%
Quality87/100
Evidence: Low Range A$0.5900 – A$0.9800

Fair value as of: Jun 24, 2026

Analysis

LTR Pharma Limited (LTP) currently trades at A$0.5650, while our model-based Fair Value estimate is A$0.7800 — implying the stock looks roughly 38.1% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is LTR Pharma Limited (LTP) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.7800 versus a price of A$0.5650 — about +38% (undervalued). Model-based estimate, not financial advice.
What is the fair value of LTP?
Our 21-model fair value for LTR Pharma Limited is A$0.7800 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$0.5650.
What is the quality score of LTP?
LTR Pharma Limited has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.